銀休特 PODD 深 滬
已收盤 01-02 16:00:00 美东时间
282.92
-1.320
-0.46%
華盛通- 最 高286.515
- 今 開285.46
- 成交量 45.68万股
- 最 低 280.18
- 昨 收 284.24
- 總市值 199.10亿
- 52周最高 354.88
- 市盈率 靜 48.91
- 換手率 0.65%
- 52周最低 230.05
- 委 比 87.50%
- 總股本 7037.49万
- 歷史最高 354.88
- 量 比 1.27
- 振 幅 2.23%
- 歷史最低 14.00
- 每 手 1
- 風險率 27.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
2025-12-19 10:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
2025-12-17 10:46
Evercore ISI Group Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $370
Evercore ISI Group analyst Daniel Markowitz initiates coverage on Insulet (NASDAQ:PODD) with a Outperform rating and announces Price Target of $370.
2025-12-16 21:58
A Look Into Insulet Inc's Price Over Earnings
In the current market session, Insulet Inc. (NASDAQ:PODD) share price is at $29...
2025-12-12 04:00
Stock index futures slide as Oracle sinks post-earnings
Stock index futures pointed to a lower open Thursday after Oracle (ORCL) posted mixed results, pressuring the AI trade. S&P 500 futures (SPX) declined by -0.57%, Nasdaq 100 futures (US100:IND) fell by...
2025-12-11 19:08
S&P 500 Flirts With Records, Netflix Drops After Warner Bros Deal: What's Moving Markets Friday?
Major Wall Street indexes were slightly higher by midday Friday, supported by economic data that strengthened expectations of a Federal Reserve interest rate cut next week.
2025-12-06 02:37
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
2025-11-24 11:23
BTIG Maintains Buy on Insulet, Raises Price Target to $380
BTIG analyst Marie Thibault maintains Insulet (NASDAQ:PODD) with a Buy and raises the price target from $370 to $380.
2025-11-21 18:34
